Our Matters for Sanofi

Business Litigation:

  • Product liability class action v. Genzyme and Mount Sinai Medical School
  • Novo Nordisk false advertising litigation
  • Derivative demands/litigation response
  • M&A/deal litigation


  • Combination with Sanofi
  • Acquisition of Lemtrada and other products from Bayer
  • Divestiture of Genetics and Diagnostics divisions
  • Acquisition of Bone Care
  • Acquisition of Caprelsa


  • Treatment of Multiple Sclerosis
  • Inventorship for MS applications
  • Humanized anti-CD52 antibodies

General Representation:

  • Corporate governance and disclosure advice
  • Debt and equity securities offerings
  • Elimination of tracking stock
  • FDA including FDAMA Section 114 and other regulatory
  • MIWG


  • Alnylam collaboration and equity investment
  • Voyager collaboration and equity investment
  • Licensing advice with respect to UCSF and Airway
  • Mobile apps – regulatory and licensing advice

Securities Litigation:

  • Riggs and Lewis v. Genzyme et al. – tracking stock litigation
  • Miscellaneous enforcement matters
  • Securities class action re: Sanofi-Aventis


  • Project Titan
  • China biologics and IP concerns
  • Pharmacy Benefits Management Project
Back to top of page
Cookie Settings